New hope for advanced colon cancer: drug combo trial launches
NCT ID NCT07358585
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug combination (HLX43 plus HLX07 or serplulimab) in people with advanced or metastatic colorectal cancer that has stopped responding to standard first-line treatment. About 126 participants will receive the experimental therapy to see if it can shrink tumors or slow disease progression. The goal is to find a better treatment option for those with limited choices.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, 716099, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.